380 related articles for article (PubMed ID: 25242081)
1. Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells.
Wang S; Chen R; Zhong Z; Shi Z; Chen M; Wang Y
Am J Chin Med; 2014; 42(5):1279-300. PubMed ID: 25242081
[TBL] [Abstract][Full Text] [Related]
2. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
4. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
[TBL] [Abstract][Full Text] [Related]
5. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
Chung SS; Vadgama JV
Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
[TBL] [Abstract][Full Text] [Related]
6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
Liu L; Ju Y; Wang J; Zhou R
Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
Zan L; Chen Q; Zhang L; Li X
Bioengineered; 2019 Dec; 10(1):374-382. PubMed ID: 31431131
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
Farabegoli F; Papi A; Orlandi M
Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
[TBL] [Abstract][Full Text] [Related]
11. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
12. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
13. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis.
Mittal A; Pate MS; Wylie RC; Tollefsbol TO; Katiyar SK
Int J Oncol; 2004 Mar; 24(3):703-10. PubMed ID: 14767556
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
[TBL] [Abstract][Full Text] [Related]
16. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
Wang S; Wang L; Chen M; Wang Y
Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
[TBL] [Abstract][Full Text] [Related]
17. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
Yunos NM; Beale P; Yu JQ; Huq F
Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
[TBL] [Abstract][Full Text] [Related]
18. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Qian F; Wei D; Zhang Q; Yang S
Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma.
Firouzi Amoodizaj F; Baghaeifar S; Taheri E; Farhoudi Sefidan Jadid M; Safi M; Seyyed Sani N; Hajazimian S; Isazadeh A; Shanehbandi D
J Biochem Mol Toxicol; 2020 Jun; 34(6):e22486. PubMed ID: 32128952
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]